Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.

Lamy A, Sandhu RK, Tong W, McIntyre WF, Lopes RD, Granger CB, Wright DJ, Nielsen JC, Kutyifa V, Erath JW, Alings M, Birnie DH, Atar D, Hohnloser SH, Linde C, Kautzner J, Benezet-Mazuecos J, Camm AJ, Sticherling C, Gold MR, Larroudé CE, Healey JS

Open source

DOI: 10.1093/europace/euaf195
Published: 2025 Sep 1
Container: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/europace/euaf195,
  title = {Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.},
  author = {Lamy A and Sandhu RK and Tong W and McIntyre WF and Lopes RD and Granger CB and Wright DJ and Nielsen JC and Kutyifa V and Erath JW and Alings M and Birnie DH and Atar D and Hohnloser SH and Linde C and Kautzner J and Benezet-Mazuecos J and Camm AJ and Sticherling C and Gold MR and Larroudé CE and Healey JS},
  year = {2025},
  journal = {Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology},
  doi = {10.1093/europace/euaf195},
  url = {https://doi.org/10.1093/europace/euaf195}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.
AU  - Lamy A
AU  - Sandhu RK
AU  - Tong W
AU  - McIntyre WF
AU  - Lopes RD
AU  - Granger CB
AU  - Wright DJ
AU  - Nielsen JC
AU  - Kutyifa V
AU  - Erath JW
AU  - Alings M
AU  - Birnie DH
AU  - Atar D
AU  - Hohnloser SH
AU  - Linde C
AU  - Kautzner J
AU  - Benezet-Mazuecos J
AU  - Camm AJ
AU  - Sticherling C
AU  - Gold MR
AU  - Larroudé CE
AU  - Healey JS
PY  - 2025
JO  - Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
DO  - 10.1093/europace/euaf195
UR  - https://doi.org/10.1093/europace/euaf195
ER  -

APA

A, L., RK, S., W, T., WF, M., RD, L., CB, G., DJ, W., JC, N., V, K., JW, E., M, A., DH, B., D, A., SH, H., C, L., J, K., J, B., AJ, C., C, S., MR, G., CE, L., & JS, H. (2025). Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. https://doi.org/10.1093/europace/euaf195

Source records

pubmed · retrieved 2026-09-25T20:18:25.843Z
europe-pmc · retrieved 2026-09-25T20:18:25.861Z